RT Journal Article
SR Electronic
T1 Vitamin D in Preclinical Models of Fatty Liver Disease
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 527
OP 534
DO 10.21873/anticanres.13981
VO 40
IS 1
A1 ERSIN KARATAYLI
A1 CAROLINE S. STOKES
A1 FRANK LAMMERT
YR 2020
UL http://ar.iiarjournals.org/content/40/1/527.abstract
AB Simple steatosis in non-alcoholic fatty liver disease (NAFLD) progresses to non-alcoholic steatohepatitis (NASH) when excessive fat accumulation is accompanied by ballooning, inflammation, and progressive hepatocellular injury. Due to the increasing global incidence of NAFLD/NASH and the lack of effective drugs, current treatment options are currently dominated by lifestyle interventions, including dietary and physical activity modifications. In this regard, vitamin D has received widespread attention in recent years. In line with its pleiotropic physiological effects, preclinical animal models and patient cohorts have demonstrated anti-inflammatory, anti-fibrotic and anti-proliferative effects of vitamin D on NAFLD and NASH. Several animal models have confirmed the association of vitamin D deficiency and NALFD/NASH severity in humans and revealed potential benefits of dietary vitamin D supplementation. These preclinical models also provide critical guidance to define the roles and therapeutic potential of vitamin D as well as its downstream functional mechanisms in the pathogenesis of fatty liver disease. This review summarizes vitamin D research in currently available animal models of fatty liver disease.